4d Pharma PLC (LON:DDDD)’s stock price traded up 1.6% during trading on Wednesday . The company traded as high as GBX 130 ($1.70) and last traded at GBX 126 ($1.65), 65,745 shares changed hands during mid-day trading. An increase of 294% from the average session volume of 16,686 shares. The stock had previously closed at GBX 124 ($1.62).

The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.11 and a current ratio of 6.41. The stock’s 50 day moving average price is GBX 87.28 and its 200 day moving average price is GBX 100.70. The company has a market capitalization of $82.52 million and a P/E ratio of -3.48.

4d Pharma Company Profile (LON:DDDD)

4D pharma plc engages in the research, development, and production of live biotherapeutic products. The company's development programs include Blautix for irritable bowel syndrome and Thetanix for paediatric crohn's disease, as well as Rosburix for Paediatric Ulcerative Colitis. It also develops immuno-oncology products, including MRx0518 for solid tumors; respiratory products, such as MRx0004 for asthma and MRx0001 for allergic asthma; autoimmune products comprising MRx0002 for multiple sclerosis and MRx0006 for rheumatoid arthritis; and CNS products for autism.

Further Reading: What is the Moving Average Convergence Divergence (MACD) oscillator?

Receive News & Ratings for 4d Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 4d Pharma and related companies with MarketBeat.com's FREE daily email newsletter.